Ideally, genetically modified animal models of AD not only have to replicate some of the hallmark neuropathology, such as plaque-like amyloid accumulations and tau deposition, but also should reproduce some of the cognitive impairments relevant to the disease. The gene discussed is MAPT; the disease is Alzheimer disease.